Testing new drug combinations for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial is testing three different combinations of existing and new drugs for advanced or metastatic colorectal cancer that hasn't improved with standard treatments or has spread to the liver. The goal is to see which combination works best and is safe for patients like you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced or metastatic colorectal cancer that is MSS (microsatellite stable) and confirmed by a lab test.
- Your cancer is measurable on scans (RECIST 1.1).
- You have fully recovered from previous treatment side effects (except hair loss).
- Depending on the group (Arm), you have either progressed on standard treatments (irinotecan, oxaliplatin, fluoropyrimidine, and anti-EGFR if applicable), or you are eligible for maintenance therapy, or for FOLFIRI chemotherapy.
- Your blood cell counts, kidney, liver, and other lab tests meet specific levels (like white blood cells, platelets, hemoglobin, bilirubin, and kidney function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination for people with advanced colorectal cancer that cannot be removed by surgery. It aims to see if the treatment can shrink tumors and help patients live longer.
This trial tests a combination of three drugs (irinotecan liposomes, cetuximab, and vemurafenib) for people with advanced colorectal cancer that has a specific genetic change (BRAF V600E mutation) and did not respond to first treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This study is testing a combination of drugs for colorectal cancer that has spread and hasn't responded to first-line treatment. It aims to see if these drugs can help control the cancer and improve outcomes for people in your situation.
This study tests a new combination of drugs, including an immunotherapy and a targeted therapy, for colorectal cancer that has spread. The goal is to see if this combination can help shrink tumors or slow the cancer. It is designed for people who have not yet received treatment for metastatic disease.
This trial tests a new combination of drugs (liposomal irinotecan, 5-FU/LV, and bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this treatment is safe and effective in shrinking tumors and improving outcomes.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
Hear when a new Metastatic Microsatellite Stable Colorectal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.